🔗 Share this article WHO Sounds Warning Over Severe Scarcity of Obesity Injections Less than 10% of patients who could benefit from weight-loss injections including Wegovy are able to get them, caution the World Health Organization as it publishes its inaugural guidance on the medications. With in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable access to this class of drugs. Based on estimates, more than two billion will be living with obesity by 2030 if no action is taken. "Our latest guidelines affirms that excess weight is a long-term condition that can be addressed with comprehensive and continuous support," said the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are key barriers to broad availability to the jabs that can help people shift substantial weight, explains the body. Weight-Loss Drug Scarcity Even under the present most optimistic outlook, the manufacturing of GLP-1 therapies could only cover about 100 million people – fewer than 10% of the global need, as stated by the health organization. The advice urges countries and companies to widen availability, via measures such as voluntary licensing. A patent on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in several nations in 2026. The Way Weight-Loss Drugs Operate The injections mimick a biological compound to delay gastric emptying, reduce hunger and enhance feelings of fullness so people eat less. Patients commonly see weight reduction after several weeks of beginning the weekly injections. Studies indicates users may regain a significant portion after a year of stopping the medication, as their usual hunger return. To be above a healthy weight raises your risk for developing health problems, including type 2 diabetes, heart disease, stroke, and specific malignancies. Obesity affects individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, as per the WHO.
Less than 10% of patients who could benefit from weight-loss injections including Wegovy are able to get them, caution the World Health Organization as it publishes its inaugural guidance on the medications. With in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable access to this class of drugs. Based on estimates, more than two billion will be living with obesity by 2030 if no action is taken. "Our latest guidelines affirms that excess weight is a long-term condition that can be addressed with comprehensive and continuous support," said the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are key barriers to broad availability to the jabs that can help people shift substantial weight, explains the body. Weight-Loss Drug Scarcity Even under the present most optimistic outlook, the manufacturing of GLP-1 therapies could only cover about 100 million people – fewer than 10% of the global need, as stated by the health organization. The advice urges countries and companies to widen availability, via measures such as voluntary licensing. A patent on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in several nations in 2026. The Way Weight-Loss Drugs Operate The injections mimick a biological compound to delay gastric emptying, reduce hunger and enhance feelings of fullness so people eat less. Patients commonly see weight reduction after several weeks of beginning the weekly injections. Studies indicates users may regain a significant portion after a year of stopping the medication, as their usual hunger return. To be above a healthy weight raises your risk for developing health problems, including type 2 diabetes, heart disease, stroke, and specific malignancies. Obesity affects individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, as per the WHO.